NCT06974851View on ClinicalTrials.gov

A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Bstructive Sleep Apnea (OSA) and Obesity

Interventions

DRUG

HRS9531

HRS9531

DRUG

HRS9531placebo

HRS9531placebo

Trial Locations (1)

100034

Beijing Hospital, Beijing

All Listed Sponsors

lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY